

**Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board
Meeting by Zoom Webinar
Wednesday, June 26, 2024, 9 a.m. to 4 p.m.**

Agenda		
Time	Topic	Presenter
9 a.m.	Welcome & Introductions Pharmacy & Therapeutics (P&T) Committee Convenes (Reviews drug classes for the WA PDL)	Kavita Chawla, Committee Chair
	Antiemetics – Archive <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Andrea Vintro, DERP
	Asthma controllers – Archive <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Andrea Vintro, DERP
	Asthma quick relief – Archive <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Andrea Vintro, DERP
	Overactive bladder – Archive <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Andrea Vintro, DERP
	Long-acting opioids – Archive <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Andrea Vintro, DERP
	Archive Drug Class Motion <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Kavita Chawla, Committee Chair
	Pharmacy & Therapeutics Committee Adjourns Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Kavita Chawla, Committee Chair
	DUR Utilization	Ryan Taketomo, HCA Marissa Tabile, HCA
	Antidiabetics <ul style="list-style-type: none"> • Cellular Therapy <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
	Cardiovascular Agents <ul style="list-style-type: none"> • Misc <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	Hematopoietic Agents <ul style="list-style-type: none"> • Stem Cell Mobilizers <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
	Asthma and COPD Agents <ul style="list-style-type: none"> • Monoclonal Antibodies <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
	ADHD / Anti-Narcolepsy <ul style="list-style-type: none"> • Dopamine And Norepinephrine Reuptake Inhibitors (DNRI) • Non-Stimulants • Stimulants - Long Acting • Stimulants - Misc • Stimulants - Short Acting <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
	Antipsychotics / Antimanic Agents <ul style="list-style-type: none"> • Antipsychotics - 2nd Generation • Antipsychotics - Combinations • Parkinsons Psychotic Disorder • Combination Psychotherapeutics <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
	Bone Density Regulators <ul style="list-style-type: none"> • Rank Ligand Inhibitors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
	Allergy <ul style="list-style-type: none"> • Allergenic Extracts / Biologicals – Oral Asthma and COPD Agents <ul style="list-style-type: none"> • Anticholinergics • Inhaled Corticosteroid Combinations • Inhaled Corticosteroids • Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations • Long Acting Muscarinic Agents • Phosphodiesterase 4 Inhibitors Endocrine And Metabolic Agents <ul style="list-style-type: none"> • Growth Hormone Releasing Hormones (GHRH) Hematopoietic Agents <ul style="list-style-type: none"> • Erythroid Maturation Agents • Erythropoiesis-Stimulating Agents (ESAS) • Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors • Thrombopoiesis (TPO) Stimulating Proteins Oncology Agents <ul style="list-style-type: none"> • Androgen Biosynthesis Inhibitors - Oral • Antiandrogens – Oral • Cyclin Dependent Kinases (CDK) Inhibitors – Oral • Hedgehog Pathway Inhibitors – Oral • MTOR Kinase Inhibitors – Oral • Retinoids – Oral 	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments.*

Committee discussion and motions will follow stakeholder comments.

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> • Topoisomerase Inhibitors – Oral • Antiestrogens – Oral • Imidazotetrazines – Oral <p>Respiratory Agents</p> <ul style="list-style-type: none"> • Pulmonary Fibrosing Agents <p>Smoking Deterrents</p> <ul style="list-style-type: none"> • Misc – Other <p>All classes in this section:</p> <ul style="list-style-type: none"> • Stakeholder input* • Motion 	
4 p.m.	Drug Utilization Review (DUR) Board Adjourns	Kavita Chawla, Committee Chair

For all Apple Health (Medicaid) questions:

1. Go to [HCA Support](#).
2. Click **Public**. You will need a SecureAccess Washington (SAW) account. ([View instructions for accessing SAW.](#))
3. Once you have logged into SAW, you will see the HCA Support portal.
4. Click **Make a Request**.
5. Click the **Apple Health Pharmacy** tile. This will take you to the online form.



** Stakeholders will be allowed 3 minutes for comments.
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.